EUCTR2018-001268-40-GB进行中（未招募）1 期
Hydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial - HAVE
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 76
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Are at least 18 years of age at screening.
- •2. Have a clinical diagnosis of Granulomatosis Polyangiitis (GPA) or a diagnosis of Microscopic Polyangiitis (MPA) or a diagnosis of Eosinophilic Granulomatosis with Polyangiitis (EGPA) according to the Chapel Hill criteria (Appendix 1).
- •3. Have a Birmingham Vasculitis Activity Score >3 BVAS v.3 (Appendix 2) with minor BVAS items only (no major BVAS items) and be receiving maintenance therapy at a stable dose for 4 weeks prior to randomisation. BVAS should be > 3 at screening and at randomisation.
- •4. Patients receiving corticosteroids for reasons other than vasculitis must be on a stable regimen for four weeks prior to randomisation.
- •5. A female patient is eligible to enter the study if she is:
- •Not pregnant or nursing
- •Of non-childbearing potential (i.e., women who have had a hysterectomy, are postmenopausal, defined as =1 year without menses, have both ovaries surgically removed or have documented tubal ligation or other permanent sterilization procedure); or
- •Of childbearing potential. These women must have a negative urine pregnancy test at screening and at baseline and be using at least one effective method of contraception. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. Consistent and correct use of one of the following acceptable methods of birth control for 1 month prior to the start of the study agent, during the study, and 16 weeks after the last dose of study agent:
- •oOral contraceptive, either combined or progestogen alone
- •oInjectable progestogen
- •oImplants of levonorgestrel or etonogestrel
- •oEstrogenic vaginal ring
- •oPercutaneous contraceptive patches
- •oIntrauterine device (IUD) or intrauterine system (IUS) with <1% failure rate as stated in the product label
- •6. No contraindications to hydroxychloroquine therapy and normal baseline visual fields at screening.
- •7. Willing and able to give written informed consent to participate in the trial.
- •8. Patients should have sufficient English in order to provide informed consent and complete the patient questionnaires.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 76
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 76
排除标准
- •1. Patients currently taking hydroxychloroquine or related antimalarial such as mepacrine or chloroquine.
- •2. Patients with eGFR <30 ml/min.
- •3. Patients weighing <40kg.
- •4. Sensitivity, anaphylaxis or allergy to hydroxychloroquine or any other 4-aminoquinoline compound.
- •5. Known glucose 6 phosphate dehydrogenase deficiency.
- •6. Known lactose intolerance.
- •7. Evidence of plaque psoriasis.
- •8. Concomitant use of the following medications:
- •Tumour necrosis factor inhibitor treatment (e.g. etanercept)
- •Cyclophosphamide
- •Alemtuzumab
- •Any experimental or biological therapies
- •Intravenous, intramuscular or sub-cutaneous immunoglobin
- •Plasma exchange
- •Antithymocyte globulin
- •Live vaccines
- •9. B cell depleting therapy (rituximab) for remission induction. Rituximab maintenance therapy is permitted.
- •10. Severe or rapidly progressive ANCA vasculitis with at least one major BVAS item.
- •11. Have clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to vasculitis (i.e., cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, malignancy or infectious disease) which, in the opinion of the principal investigator, could confound the results of the study or put the patient at undue risk.
- •12. Have a history of malignant neoplasm within the last 5 years, except for adequately treated cancers of the skin (basal or squamous cell) or carcinoma in situ of the uterine cervix.
- •13. Have current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence within 364 days prior to randomisation. A urine drug screen should be performed and confirmed negative prior to study entry.
- •14. Have a historically positive test or test positive at screening for hepatitis B surface antigen, hepatitis B core antibody or hepatitis C antibody or are known to be HIV-1 positive.
- •15. Have a Grade 3 or greater laboratory abnormality based on the CTCAE toxicity scale (version 5), unless considered by the investigator to be related to the underlying disease or induction therapy.
- •16. Screening 12-lead ECG that demonstrates clinically relevant abnormalities that may affect patient safety or interpretation of study results, including: – QT interval corrected using the same consistent formula at each visit (QTc) > 470 msec for female > 450 msec for male patients demonstrated by at least two ECGs.
- •17. Participation in any other interventional trial within the last 6 months.
- •18. Have a current symptomatic COVID-19 infection.
- •19. Have been admitted to the ICU in the past 6 months due to a COVID-19 infection.
研究者
相似试验
进行中（未招募）
4 期
Hydroxychloroquine in ANCA Vasculitis Evaluation (HAVEN)Microscopic polyangiitisMicroscopic polyangiitis, ANCA vasculitisMusculoskeletal DiseasesISRCTN79334891Guy's and St Thomas' NHS Foundation Trust76
进行中（未招募）
4 期
Hydroxychloroquine in ANCA Vasculitis EvaluationWegener GranulomatosisANCA Associated VasculitisChurg-Strauss SyndromeMicroscopic PolyangiitisNCT04316494Guy's and St Thomas' NHS Foundation Trust43
进行中（未招募）
不适用
Hydroxychloroquine in the prevention of cardiovascular events in high risk patientsCardiovascular diseaseEUCTR2015-000233-73-FIHelsinki University Central Hospital200
进行中（未招募）
不适用
Efficacy of the treatment with hydroxychloroquine in non responders HIV-infected HAART-treated patients - NDHIV infection (immunological nonresponders).MedDRA version: 9.1Level: LLTClassification code 10008922EUCTR2009-012499-28-ITAZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)40
尚未招募
3 期
Efficacy of hydroxychloroquine in graves disease in addition to antithyroid drugs.CTRI/2023/07/054894IPQA laboratories